EICHOR
● Completed
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Condition: Multiple Myeloma · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (73)
| University of Alabama Birmingham | Birmingham, Alabama, United States | — |
| Arizona Oncology Associates, PC - HAL | Glendale, Arizona, United States | — |
| Cancer Treatment Center of America Phoenix | Goodyear, Arizona, United States | — |
| University of California San Diego (UCSD) - The Rebecca and John Moores Cancer Center | La Jolla, California, United States | — |
| UCLA David Geffen School of Medicine | Los Angeles, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | — |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | — |
| University of Colorado Health | Fort Collins, Colorado, United States | — |
| Yale University Medical Center | New Haven, Connecticut, United States | — |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| Cancer Specialists of North Florida | Jacksonville, Florida, United States | — |
+ 61 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03901963